{"ticker": {"uuid": "1918e4cd-5d17-42c0-a068-f48122b68052", "symbol": "CRL", "name": "Charles River Laboratories", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River\u2019s Cell Therapy Moat or Stretch CRL Too Thin?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/does-arovella-car-inkt-ngs-101132012.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T10:11:32+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call", "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) will announce its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. Following the release, the company will host a conference call on the same day at 9:00 a.m. ET to discuss the resu", "url": "https://www.biospace.com/press-releases/charles-river-laboratories-schedules-second-quarter-2026-earnings-release-and-conference-call", "source_name": "BioSpace", "published_at": "2026-07-16T07:45:30", "published_display": "16 Jul 2026 07:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day", "summary": "Charles River Laboratories International Inc. (CRL) stock declined 1.29% to $228.22, despite an overall positive trading day for the stock market where the S&P 500 and Dow Jones Industrial Average rose. The company's stock closed 4.05% below its 52-week high of $237.86.", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-outperforms-competitors-despite-losses-on-the-day-1dccb3ad-d53259f96bf2?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-16T00:38:35", "published_display": "16 Jul 2026 00:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River investors will get Q2 results before market open Aug. 5", "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss these results. I", "url": "https://www.stocktitan.net/news/CRL/charles-river-laboratories-schedules-second-quarter-2026-earnings-pouiiyyixm9e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:03:57", "published_display": "15 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released \u2014 Profiles Charles River, Labcorp, Eurofins and Evotec", "summary": "The global market for Cell-Based Assay Services for Preclinical Use Only is projected to grow from $4.47 billion in 2025 to $12.93 billion by 2035, driven by demand for drug discovery and personalized medicine. The report highlights cytotoxicity assays and plate-based luminometry", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327516/0/en/cell-based-assay-services-for-preclinical-use-only-global-market-report-2026-released-profiles-charles-river-labcorp-eurofins-and-evotec.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T05:25:00", "published_display": "15 Jul 2026 05:25", "sentiment": "positive", "sentiment_pct": 86, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQLU81ZVUwS0M1dV9uZm92WjZJZ0hYM2VCS2JtOWtZWXJyNU5DS1Q0M2VscmpkbEQtLU41Q2RzZEF5WG11OWNITDhzZkJ4TUpJa3hqdXlnZGhKa0FuQnVqbEFFTnF6Wk0zbEJlWTJvbm5Sd3dQYkx5TmYxMjMtMDFQeUNDT2J2a1A3TllGdXdVR1JkVWtoVktRR1hDaS1GUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:10:05+00:00", "published_display": "14 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRL5145816 Bond Risk Profile", "summary": "This article provides a risk profile for the CRL5145816 bond issued by Charles River Laboratories International, Inc., with a 4.0% coupon and maturing on March 15, 2031. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issu", "url": "https://www.tradingview.com/symbols/FINRA-CRL5145816/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T09:38:06", "published_display": "14 Jul 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs stock reflects steady demand for preclinical research services", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPUzhGcUFLaWNHSnI3bjNiUnBOSGhmMkdKVlhRcDFUVWdiakR5dTB5bnk0aW5DaFBpWUpjT0NpUU5DMDVzZHVnaVV1NHc2VkthY0dCSms3V0RhTVpGRmVpUks5NEdMSXZBdjVUQ3hDaUZ3LUd2TXVMUVlTbWN1VlVlNTZEcUtrNi0xTklVV3FWNGZGTHVFR2gxTmFNUUVBZHdwN1V6emloQUFQdTlCYjNaVHpqcW1SeEpnX0NNLTVld3ZpX2hXV0xLVWVlOA?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-13T22:40:32+00:00", "published_display": "13 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Charles River Laboratories International Inc. (CRL) fell 1.57% during Monday's trading session, closing at $229.75. This underperformance occurred on a day when the broader stock market, represented by the S&P 500 and Dow Jones Industrial Average, also experienced decli", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-underperforms-monday-when-compared-to-competitors-f4af1698-8777bb94c186?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T17:16:00", "published_display": "13 Jul 2026 17:16", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-adjusts-price-target-charles-153548846.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:35:48+00:00", "published_display": "13 Jul 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $237.79, Implies 2% Upside", "summary": "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock from $234.64 to $237.79, based on estimates from 14 analysts. This updated target suggests a potential 2% upside from the July 10 closing price. The consensus rat", "url": "https://www.tradingview.com/news/tradingview:af5a24fa77efd:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-237-79-implies-2-upside/", "source_name": "TradingView", "published_at": "2026-07-13T16:20:32", "published_display": "13 Jul 2026 16:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River to Provide GMP NGS Services to Arovella", "summary": "Charles River Laboratories International Inc. has partnered with Arovella Therapeutics Ltd to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. This collaboration will support Arovella in developing its Invariant Natura", "url": "https://www.contractpharma.com/breaking-news/charles-river-to-provide-gmp-ngs-services-to-arovella/", "source_name": "Contract Pharma", "published_at": "2026-07-13T15:38:45", "published_display": "13 Jul 2026 15:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating", "summary": "Baird has raised its price target for Charles River Laboratories International (CRL) to $255 from $213, while reiterating an Outperform rating on the stock. This adjustment reflects Baird's continued positive outlook on the company's financial prospects and market position.", "url": "https://www.moomoo.com/news/post/72867443/baird-adjusts-charles-river-laboratories-international-price-target-to-255?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:07:30", "published_display": "13 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-charles-131247448.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:12:47+00:00", "published_display": "13 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $235.64, Implies 1% Upside", "summary": "The average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock has been raised to $235.64 from $232.5 by 14 analysts, implying a 1% potential upside from its closing price on July 10. The consensus rating among 20 analysts remains \"Buy,\" with a b", "url": "https://www.tradingview.com/news/tradingview:af5a24fa77efd:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-235-64-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-07-13T13:20:10", "published_display": "13 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/charles-river-provides-ngs-services-120000457.html", "source_name": "Business Wire", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Charles River\u2019s gene sequencing work supports ALA-101 cancer cell therapy trials", "summary": "Charles River Laboratories (NYSE: CRL) announced a collaboration with Arovella Therapeutics (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services. This partnership will support Arovella's development of its ALA-101 iNKT cell therapy pla", "url": "https://www.stocktitan.net/news/CRL/charles-river-provides-ngs-services-to-arovella-therapeutics-73ufqx0a49sj.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:03:16", "published_display": "13 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics", "summary": "Charles River Laboratories will provide cell sequencing services to Arovella Therapeutics, supporting the latter's efforts to develop alternative cancer treatments. This collaboration aims to accelerate progress in therapeutic approaches by leveraging Charles River's expertise in", "url": "https://www.marketscreener.com/news/charles-river-laboratories-to-provide-cell-sequencing-services-to-arovella-therapeutics-ce7f5edcd88bf52d", "source_name": "marketscreener.com", "published_at": "2026-07-13T10:36:00", "published_display": "13 Jul 2026 10:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International (CRL) Expands AI Pathology Platform, Is The Valuation Upside Already Priced In?", "summary": "Charles River Laboratories International (CRL) has expanded its AI-enabled digital pathology platform, coinciding with the stock reaching a 52-week high and attracting investor attention. While a popular narrative suggests the company is 25.6% undervalued with a fair value of $31", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-expands-ai-path", "source_name": "Simply Wall Street", "published_at": "2026-07-12T20:37:26", "published_display": "12 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories stock hits 52-week high at $236.67 By Investing.com", "summary": "Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $236.67, with a market capitalization of $11.36 billion. This significant increase of 47.31% over the past year reflects strong investor confidence despite the stock appearing overvalued a", "url": "https://ng.investing.com/news/stock-market-news/charles-river-laboratories-stock-hits-52week-high-at-23667-93CH-2595087", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T15:07:27", "published_display": "10 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories stock hits 52-week high at $236.67", "summary": "Charles River Laboratories (CRL) stock reached a new 52-week high of $236.67, with shares trading at $237.85, reflecting a significant 47.31% increase over the past year. This achievement is driven by robust performance and investor confidence, supported by strategic expansions i", "url": "https://za.investing.com/news/stock-market-news/charles-river-laboratories-stock-hits-52week-high-at-23667-93CH-4364503", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T15:07:23", "published_display": "10 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day", "summary": "Charles River Laboratories International Inc. (CRL) stock rose 4.30% to $233.60 on Thursday, outperforming the broader market. This strong performance ended a two-day losing streak for the company's stock. The S&P 500 Index also saw gains, rising 0.81%, while the Dow Jones Indust", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-outperforms-competitors-on-strong-trading-day-0b5bb140-94afa208cc01", "source_name": "MarketWatch", "published_at": "2026-07-09T20:30:00", "published_display": "09 Jul 2026 20:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards two healthcare companies: Harmony Biosciences Holdings (HRMY) and Charles River Labs (CRL). Mizuho Securities reiterated a Buy rating for Harmony Biosciences with a $50 price target, while Citi maintained a Buy rating for", "url": "https://www.theglobeandmail.com/investing/markets/stocks/HRMY-Q/pressreleases/3201591/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T16:12:12", "published_display": "09 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220", "summary": "Morgan Stanley has increased its price target for Charles River Laboratories International (NYSE: CRL) to $260, up from the previous $220, while maintaining an \"Equal-Weight\" rating on the stock. This adjustment reflects a revised valuation perspective by the firm.", "url": "https://www.moomoo.com/news/post/72724605/morgan-stanley-adjusts-price-target-on-charles-river-laboratories-international?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T15:38:46", "published_display": "09 Jul 2026 15:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $226.79, Implies 1% Upside", "summary": "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock to $226.79, up from $223.93. This new target implies approximately 1% potential upside based on the July 8 closing price, with individual forecasts ranging from $", "url": "https://www.tradingview.com/news/tradingview:d9d6cda2e7d21:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-226-79-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-07-09T13:20:05", "published_display": "09 Jul 2026 13:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories highlights its role in drug development. Steady operations underpin the s", "summary": "Charles River Laboratories is a crucial contract research organization supporting the biotech and pharma industries from early discovery through preclinical development. The company's services, which include in vivo models, in vitro assays, and specialized safety studies, are vit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/charles-river-laboratories-highlights-its-role-in-drug-development-steady/69728625", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T08:26:00", "published_display": "09 Jul 2026 08:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree", "summary": "The article reports that Charles River Laboratories International stock has surged by 27%, marking a 9-day winning spree. No further details about the reasons for this surge or financial specifics are provided. The content primarily consists of a headline and website navigational", "url": "https://www.trefis.com/data/companies/CRL/no-login-required/0GFR2EYv/Charles-River-Laboratories-International-Stock-Surges-27-With-A-9-Day-Winning-Spree", "source_name": "Trefis", "published_at": "2026-07-08T22:37:28", "published_display": "08 Jul 2026 22:37", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories highlights its role in drug development as investors assess long-term gro", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPeXZ6cS0tSG4tdnJHSXBiUThJN0tZMlU3b2pXa1pmWllsazBqV2VCb1Rob0JTdHdRY2NDRy1pWTRnTEZCMGozZjYwalVaa3dUeFRVMUo1eWFBUUpza1N6WEliQzBmYk9HNVl4MUZSelFXRktBbTc0TWFWVmM3TGE5c0dHbGVHSWRNOUpMS3o4ZmU1S1VZQWhlZklBYjhKS3NxZng2WEdHQ2l3bXY5bWc1bTVzaUg0SnBVQlRZU3ROcExxMjVKQ3RZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T06:59:40+00:00", "published_display": "08 Jul 2026 06:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs business profile and stock context", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNemVURTByY0w5TmtWdDVJVlFvTVZJWXAxZEdWODBySkE3aWQzdFlIZDRWVTVzVEh4UzlsNDcyOFNweks4cGk5RWFyc1ZoT1oyUEFnd3BXaDZqbnBBVmlBank0YzZZVEUzc1JObi1YM2FuOG9JVFZkdFlobzBxaXRzVzBhd1ZEQ3l6bktTRks5aFpmNUhleXFfeEFIendBQU5abEJZc2luMlBCdVJMRU93TTN3?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T14:23:27+00:00", "published_display": "07 Jul 2026 14:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Analyst Upgrades Signaling a Turning Point in Charles River\u2019s (CRL) Biopharma Pipeline Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNV25MMlViSHhBYWxLOFdJVUZlamI2dnl3Wk5GeC0zSUxIRTdXbk5YNTlLZThZSmxjVHlqMk5EZHptR251YzBoNEgzaFRFcXM2V1RTWDhpY0FHRjVwcVRPU21yZUJCZkMyc24wS1NJTnJvLVU3cGFraWREbV90ZFVicFF5aFNHY0xfQkkySEpWYUZlbFg1bTJaMUI0aUpKeFA3?oc=5", "source_name": "Market source", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T10:23:36+00:00", "published_display": "03 Jul 2026 10:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs faces a thin catalyst day. Focus stays on earnings and cash flow.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSm9xam1RbDREVXBRQnNhWTBjSXlUNXdQTk5ycV8tMGJPNW96MTFRcmZGeTR1eWV1elZwQ1l1T2dmLVRrejJpeDNUM2psM0NUZVVvQV9sdEstZDlNeWFhTzJ3UEpCZDlab1k2MjlVWXVUVGNLYzV3SVl3SHBCemxQWU1wTGIzVWxnMW1jbzNTQ25fREZ3eWkwWm1BSzFwZmFsY3JqYXhjYU5qc044Rkt2UHFFeGhVZDJoSFc3VENYRjc3bnpGMDJvcXlIVQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T05:44:07+00:00", "published_display": "02 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories updates operations strategy as research demand evolves", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQa21lQjV3b3FxMHJUZkY5Mmtya3FBQlRIYUNLN1QxZHV0SHBaMlZ6bGFhR3BvNlBpQnlVTkVWZ3pLeW5HaHNqR2ZCal9IWWlvLU9oSTVJTkVMSGh4M1U1eDJvbFYza3RKcW84WVc5TkRKSGxBU191eW9CMHFaSFI4dlRRR0pnX0hDZ0kwWW83RHhVamJrbjBpTkRZbVhyam5PUmFTNXRxbXU5MERuN1BpdzdwTkpBY3FEcVg1dlV6alhOYlNXU2RuN0VHZmo?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-01T15:10:51+00:00", "published_display": "01 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPRDczRlVfY2htbWR6cV9hcDZIMnVrQkFnOUxDTFkyNFd4ZXRzVUJ4SjJnczFQWHRCc1pWZUJWMm5nRUdyR0RQNGxxak04RF9Pc2xWOUt6SXlPdC1uMm5BWGs0end3M293V2hSN3MzOWR2aWVXVXkzajJZTlJLOERBeFVSZjZPWXFsQ0psaTA5eHE5T1hHTGp2RS1hUlp5dWJPWUVQWHMxQVhzekpkd0E?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPczNMN20yNHR2Yk9lOEFESTI5RkJZWFNfdm5TUmhpYjJPb2pqcG5iVC1TZlRISzN3Q0ZlY1k5TzgxdGNoSmtpM1J1dnpJVF9aTjloa1hNcXpWemNsdDQxNlpYcWlCMVJoTXkxSFFMd1MwREQ1ZU5OWFhOTUFxU0xDRi1Hc1FWQjNoSGJueFVCeDVTUjdlcmlZTVd5WjJzWnpLSU5CUEVfMTVHOUtEdW8yZ3J0VmdjbFM2NXE4N1Z3TVJKT29PaXd4Z2RVR2E?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Is Charles River Laboratories\u2019 Stock Performance Compared to Other Health Care Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQZ1RERmhfd1BTVnNjRmdKSGVMQUt3XzdYTEc3WTVfUHlkV09KRFFReVNqNVMxU0RxQXNNVEYxT1FSVjA0SkxoTjFGN3I1bU80OUtJZEo4R2FBQ1JpZzBUYUVGQ1ZhZW10WlRnTXREYk9wbERKb3dxelphZ2NqSE9qb1pCWURWcTUzYnpBUUdxVTAzWWdxWDBtRjZMSE1UaTRzd2VEMUxoY3hScENZdXc?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Stock (US1591881009): Labcorp comparison puts valuation in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNanlkemFKTjNQMXVHVngxdXRULXZCdGo2clcyaU5mYnBXcDY0emFkaDNpMHkyUXRER1pWNVJJQkFDdmlYRTI5WjNrMVQxaU5nclZ2Z19ZamNIU2hFSGFLaUU0ZEVRT2JkYWQ3QXY4TmwyVDJuNEIzcGZGdE1waF82UkdIZ3dKVHJqeThrOGhJSXpxYV9GLWhjVWRmRXp5Tk1lWWlQTHhMRW9LaUViOVZCaG5OZ2c0T21uMWVUUlpibjgyT3lsNUxZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-16T14:20:01+00:00", "published_display": "16 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Stock (US1591881009): shares in focus after recent earnings and valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNbU9salMxeWI5b3R1STZWUDF0TXhRS29RdWdya0Z4MHMwOUJ0dmZsTDVPYi05QUpnMVluYk16MVNFVW1tM2tDNUNLYWd2dzNlMmJLVTBhSmtnX3JqLWctQ3A4QVVOSDBhQ0RTdHdFcUlLcHV3UExqMFJoOUZEV3BNbUJfVnNUalZRVDhoYnpXTE0wNXZpc1BNcnE5UThOdVV2SFU2dmtPOWZVNEpob1kxaFFaUGFyaEhLYkN1TXBybmw5OHJu?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Charles River Laboratories Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZXhOem5tYVhvM3RFcE5hb29wZ3J2X3VXdXM1YXBrWjFFWUdNNWlwelNHTDhVclE2d2pzeDBMc2hEOGVsNmNZMzRKdjljai1ld052dEFaaE03QTVsODRXZFp4Wm9iNWxVUWJLX19nQVNWUDA5Z3VTeEJHcTJvZFZ1TjdOU3ZaeE5keU9abWFnYnBhVkgwNTdabE1FNXZZbWQ3cjVJ?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQTlBYSkd3SnJpZWNiZ2ZEVzFHNUtDWDF5cHlLTjhKc1lYaC1haEFUWUR1SG12WEpfdWxXR3luamlTT2kwVXpzSER5X2xwbnltYld5d0lTcnc4ak1KVTlHbXhrUGlPMW9pT0Nhb1JlT1FMQXBtZlZoVFVtRUVnbmYyQnhiby15MGdpd1FtTE5HMWQzYmxEcTJkb0JyWTBGblBKb1ppTU5IYmpJQm1DM3VxdEtmc2RQek5tX1lFSnl3U0ZCNDNYNTFvTkJrSHRNT1JrZVRnRnJTQUtZaEhUUFVkUnB3YXFWaXl5TWs5X0dGdjFEeThBU3k3WlZDaXJBNi140gGGAkFVX3lxTFBjeVRMUVluYXdBOXpRcXQ1OFZIc3pmUWNDa09EZnBXYXgwNXo2Q3dNZE9pdGdEbk9NYTZ3eEJsN21EWVYzdnZEdklmTEtOaXlWc1AzVFVCb3RJVzE3ODJwZVdSaDZNcWtwNFJyMDhRdzhtSzNxMy1VcUZHajVNSktSS09PMGtiQV9WeVN1UXpjYnpBLVowN0FaVDFwNENWS1Fpd0RqT3dBRlhjZ3VoeDFnY3B3MlhWN1lRaHFnSFpWZHBNLWt2MUFvX3ZhRkwyQkFUUkJPZ3hzLUE1bF9BdzdSQXhDcnlacEZwMkdVUXdqdVQ5VmdCY0RhWkhfejl6d2hnQUNFcGc?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Charles River (NYSE: CRL) gets 1,438-share equity grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQQzg5TEgwNUNoTFk1QXQtSDBDaEw5NWxXWmFjZkdhTWIwOE0zaDVwU25GS25XYVpCSVdLQ3ZwS3QtZFNTdmpIX1hnczQtMjFaVUFDT2k1d1MwSDktQ0JoY2dkRURuY2R0ZEFWVm5ZMW1xblBmWU5Gb0xhYkhSR0dHU1FsMW5HRkR4VXZfT1J3VWRSRkRQa3c2T3IzNEZqdTl6UkVMcFduc0lLaEFXbndtVnAtV3FSN1RtX0FDaTZuMUdxWUF1UjFiS013?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQclYwUDdHSTNXdndxcTdDbTAyOFo2c0IxX2F2eERqRHVleGVxcUZ5S2dNVE43NlR4WUNRVWRzcEdqdUpvdGZzbEhjQzdwc0FuRlVPVU1YMTB1RnlYYnpJOWROSVRCTU4zclg3NWFLdVZ4WVBUUHZ0QVFXY2ctYWIxNjV4UVpQb1QxakhFVEhfS2NoZXB0NHdqeV9aSkNEX2tnbHZ3NzNoUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQM0N0d3hxcF9xcU1ldDVDcExtUk5fMHRSakxVMXVaZ19ac2NtbU05Mk54X3hlSVZWUWh4eGdlRFg3VkJvNjV2N19Da1dYN0E3WHVDbWt0UmVodG1yX2I5emtSYUdTbDNVbGN2S29vb3pGMnE1X0tUdkNqcWRITEtiVlRnMEZVdnAwTW1uaEFKRTZWTUNLdlZhYXFYaXhDN0U5aU0wckhuRVk?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC (CRL) holds 7.0% of Charles River Labs; 3.456M shares disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPazJ6RFJqRXNqbHNWRF8wSDQxVUlaRVF4NlJDYTJHQ2xJMjRfXzFUanVzWl9FYnBEN1lUOVZuc2tNZ0ZmWkNkSjI0aDI5OHhZUC1hSmxPWUd2dFhJT3dydVNieU1PcllHaEJrd0g5U2FHbjU5NUtHT2VaOFFaQU9PcnR4RHM3Xy1mR1JHRDJfS2t4RV94T1JvWll2RHlfOTFkSDh0dXNmLTJkWWx1X2IwRGpwbnpxSHFYR1JiSVVmcGpnUU5GaU9LVF9B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs Stock: Strong Performance vs. Underlying Business Challenges - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNWkZFOGYyTVhxVFlndzc0U3ljTW1yVWVHaTZBYjhzVjJxdl8zZ1ZZVEpYaGctYWlyTHAzNUk2Uk55eHo2ZXJlcnh5cVlfR1VJeVM0cGhhck84SGpIQjZpNTY4cnlsMGZ0TzRkX01ObElFMlBTMm9haGsxOExxMlZaVHRkZUljTm1ObTZHdklXeTA1NkZGX1dwU0hvWk9xYXY4ZTRXMzdFeFcwNG8?oc=5", "source_name": "IndexBox", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Charles River Laboratories International Stock Sliding, Have You Assessed The Risk?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNcjlCYmhvV0xtajBuTmJPUDlLRzJEV0tmQ0p2bl9qZmhoLXd5SFNyN25OWnJlN1ZSTnl6aVlfRml2QnltMXZ5QUd2Q3NKVEQxTjlza1JjSW5TRXhBUjVqY0xiSGQ3LWhuSVdUbk9ydF8tbGRBRG80QzNPWl9fcVNKSHdzcUxWTzU3RTZTby1yTm5nRVZ0cWFuMWhzOFhkS3lyREZBbmFEMDBhNTZ6OVFYYkZxbmRJaEp0WXdMcF9sUGdEd0NRS0ZXWTJkWlNnRVdiSXdLcHFsbmJFclhRSDRj?oc=5", "source_name": "Trefis", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River\u2019s Cell Therapy Moat or Stretch CRL Too Thin?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/does-arovella-car-inkt-ngs-101132012.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T10:11:32+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call", "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) will announce its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. Following the release, the company will host a conference call on the same day at 9:00 a.m. ET to discuss the resu", "url": "https://www.biospace.com/press-releases/charles-river-laboratories-schedules-second-quarter-2026-earnings-release-and-conference-call", "source_name": "BioSpace", "published_at": "2026-07-16T07:45:30", "published_display": "16 Jul 2026 07:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day", "summary": "Charles River Laboratories International Inc. (CRL) stock declined 1.29% to $228.22, despite an overall positive trading day for the stock market where the S&P 500 and Dow Jones Industrial Average rose. The company's stock closed 4.05% below its 52-week high of $237.86.", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-outperforms-competitors-despite-losses-on-the-day-1dccb3ad-d53259f96bf2?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-16T00:38:35", "published_display": "16 Jul 2026 00:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River investors will get Q2 results before market open Aug. 5", "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss these results. I", "url": "https://www.stocktitan.net/news/CRL/charles-river-laboratories-schedules-second-quarter-2026-earnings-pouiiyyixm9e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:03:57", "published_display": "15 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released \u2014 Profiles Charles River, Labcorp, Eurofins and Evotec", "summary": "The global market for Cell-Based Assay Services for Preclinical Use Only is projected to grow from $4.47 billion in 2025 to $12.93 billion by 2035, driven by demand for drug discovery and personalized medicine. The report highlights cytotoxicity assays and plate-based luminometry", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327516/0/en/cell-based-assay-services-for-preclinical-use-only-global-market-report-2026-released-profiles-charles-river-labcorp-eurofins-and-evotec.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T05:25:00", "published_display": "15 Jul 2026 05:25", "sentiment": "positive", "sentiment_pct": 86, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQLU81ZVUwS0M1dV9uZm92WjZJZ0hYM2VCS2JtOWtZWXJyNU5DS1Q0M2VscmpkbEQtLU41Q2RzZEF5WG11OWNITDhzZkJ4TUpJa3hqdXlnZGhKa0FuQnVqbEFFTnF6Wk0zbEJlWTJvbm5Sd3dQYkx5TmYxMjMtMDFQeUNDT2J2a1A3TllGdXdVR1JkVWtoVktRR1hDaS1GUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:10:05+00:00", "published_display": "14 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRL5145816 Bond Risk Profile", "summary": "This article provides a risk profile for the CRL5145816 bond issued by Charles River Laboratories International, Inc., with a 4.0% coupon and maturing on March 15, 2031. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issu", "url": "https://www.tradingview.com/symbols/FINRA-CRL5145816/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T09:38:06", "published_display": "14 Jul 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs stock reflects steady demand for preclinical research services", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPUzhGcUFLaWNHSnI3bjNiUnBOSGhmMkdKVlhRcDFUVWdiakR5dTB5bnk0aW5DaFBpWUpjT0NpUU5DMDVzZHVnaVV1NHc2VkthY0dCSms3V0RhTVpGRmVpUks5NEdMSXZBdjVUQ3hDaUZ3LUd2TXVMUVlTbWN1VlVlNTZEcUtrNi0xTklVV3FWNGZGTHVFR2gxTmFNUUVBZHdwN1V6emloQUFQdTlCYjNaVHpqcW1SeEpnX0NNLTVld3ZpX2hXV0xLVWVlOA?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-13T22:40:32+00:00", "published_display": "13 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Charles River Laboratories International Inc. (CRL) fell 1.57% during Monday's trading session, closing at $229.75. This underperformance occurred on a day when the broader stock market, represented by the S&P 500 and Dow Jones Industrial Average, also experienced decli", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-underperforms-monday-when-compared-to-competitors-f4af1698-8777bb94c186?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T17:16:00", "published_display": "13 Jul 2026 17:16", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-adjusts-price-target-charles-153548846.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:35:48+00:00", "published_display": "13 Jul 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $237.79, Implies 2% Upside", "summary": "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock from $234.64 to $237.79, based on estimates from 14 analysts. This updated target suggests a potential 2% upside from the July 10 closing price. The consensus rat", "url": "https://www.tradingview.com/news/tradingview:af5a24fa77efd:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-237-79-implies-2-upside/", "source_name": "TradingView", "published_at": "2026-07-13T16:20:32", "published_display": "13 Jul 2026 16:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River to Provide GMP NGS Services to Arovella", "summary": "Charles River Laboratories International Inc. has partnered with Arovella Therapeutics Ltd to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. This collaboration will support Arovella in developing its Invariant Natura", "url": "https://www.contractpharma.com/breaking-news/charles-river-to-provide-gmp-ngs-services-to-arovella/", "source_name": "Contract Pharma", "published_at": "2026-07-13T15:38:45", "published_display": "13 Jul 2026 15:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating", "summary": "Baird has raised its price target for Charles River Laboratories International (CRL) to $255 from $213, while reiterating an Outperform rating on the stock. This adjustment reflects Baird's continued positive outlook on the company's financial prospects and market position.", "url": "https://www.moomoo.com/news/post/72867443/baird-adjusts-charles-river-laboratories-international-price-target-to-255?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:07:30", "published_display": "13 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-charles-131247448.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:12:47+00:00", "published_display": "13 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $235.64, Implies 1% Upside", "summary": "The average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock has been raised to $235.64 from $232.5 by 14 analysts, implying a 1% potential upside from its closing price on July 10. The consensus rating among 20 analysts remains \"Buy,\" with a b", "url": "https://www.tradingview.com/news/tradingview:af5a24fa77efd:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-235-64-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-07-13T13:20:10", "published_display": "13 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/charles-river-provides-ngs-services-120000457.html", "source_name": "Business Wire", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Charles River\u2019s gene sequencing work supports ALA-101 cancer cell therapy trials", "summary": "Charles River Laboratories (NYSE: CRL) announced a collaboration with Arovella Therapeutics (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services. This partnership will support Arovella's development of its ALA-101 iNKT cell therapy pla", "url": "https://www.stocktitan.net/news/CRL/charles-river-provides-ngs-services-to-arovella-therapeutics-73ufqx0a49sj.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:03:16", "published_display": "13 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics", "summary": "Charles River Laboratories will provide cell sequencing services to Arovella Therapeutics, supporting the latter's efforts to develop alternative cancer treatments. This collaboration aims to accelerate progress in therapeutic approaches by leveraging Charles River's expertise in", "url": "https://www.marketscreener.com/news/charles-river-laboratories-to-provide-cell-sequencing-services-to-arovella-therapeutics-ce7f5edcd88bf52d", "source_name": "marketscreener.com", "published_at": "2026-07-13T10:36:00", "published_display": "13 Jul 2026 10:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International (CRL) Expands AI Pathology Platform, Is The Valuation Upside Already Priced In?", "summary": "Charles River Laboratories International (CRL) has expanded its AI-enabled digital pathology platform, coinciding with the stock reaching a 52-week high and attracting investor attention. While a popular narrative suggests the company is 25.6% undervalued with a fair value of $31", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-expands-ai-path", "source_name": "Simply Wall Street", "published_at": "2026-07-12T20:37:26", "published_display": "12 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories stock hits 52-week high at $236.67 By Investing.com", "summary": "Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $236.67, with a market capitalization of $11.36 billion. This significant increase of 47.31% over the past year reflects strong investor confidence despite the stock appearing overvalued a", "url": "https://ng.investing.com/news/stock-market-news/charles-river-laboratories-stock-hits-52week-high-at-23667-93CH-2595087", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T15:07:27", "published_display": "10 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories stock hits 52-week high at $236.67", "summary": "Charles River Laboratories (CRL) stock reached a new 52-week high of $236.67, with shares trading at $237.85, reflecting a significant 47.31% increase over the past year. This achievement is driven by robust performance and investor confidence, supported by strategic expansions i", "url": "https://za.investing.com/news/stock-market-news/charles-river-laboratories-stock-hits-52week-high-at-23667-93CH-4364503", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T15:07:23", "published_display": "10 Jul 2026 15:07", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day", "summary": "Charles River Laboratories International Inc. (CRL) stock rose 4.30% to $233.60 on Thursday, outperforming the broader market. This strong performance ended a two-day losing streak for the company's stock. The S&P 500 Index also saw gains, rising 0.81%, while the Dow Jones Indust", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-outperforms-competitors-on-strong-trading-day-0b5bb140-94afa208cc01", "source_name": "MarketWatch", "published_at": "2026-07-09T20:30:00", "published_display": "09 Jul 2026 20:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards two healthcare companies: Harmony Biosciences Holdings (HRMY) and Charles River Labs (CRL). Mizuho Securities reiterated a Buy rating for Harmony Biosciences with a $50 price target, while Citi maintained a Buy rating for", "url": "https://www.theglobeandmail.com/investing/markets/stocks/HRMY-Q/pressreleases/3201591/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T16:12:12", "published_display": "09 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220", "summary": "Morgan Stanley has increased its price target for Charles River Laboratories International (NYSE: CRL) to $260, up from the previous $220, while maintaining an \"Equal-Weight\" rating on the stock. This adjustment reflects a revised valuation perspective by the firm.", "url": "https://www.moomoo.com/news/post/72724605/morgan-stanley-adjusts-price-target-on-charles-river-laboratories-international?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T15:38:46", "published_display": "09 Jul 2026 15:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories , Inc. Stock 12\u2011Month Price Target Raised to $226.79, Implies 1% Upside", "summary": "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock to $226.79, up from $223.93. This new target implies approximately 1% potential upside based on the July 8 closing price, with individual forecasts ranging from $", "url": "https://www.tradingview.com/news/tradingview:d9d6cda2e7d21:0-charles-river-laboratories-inc-stock-12-month-price-target-raised-to-226-79-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-07-09T13:20:05", "published_display": "09 Jul 2026 13:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories highlights its role in drug development. Steady operations underpin the s", "summary": "Charles River Laboratories is a crucial contract research organization supporting the biotech and pharma industries from early discovery through preclinical development. The company's services, which include in vivo models, in vitro assays, and specialized safety studies, are vit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/charles-river-laboratories-highlights-its-role-in-drug-development-steady/69728625", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T08:26:00", "published_display": "09 Jul 2026 08:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree", "summary": "The article reports that Charles River Laboratories International stock has surged by 27%, marking a 9-day winning spree. No further details about the reasons for this surge or financial specifics are provided. The content primarily consists of a headline and website navigational", "url": "https://www.trefis.com/data/companies/CRL/no-login-required/0GFR2EYv/Charles-River-Laboratories-International-Stock-Surges-27-With-A-9-Day-Winning-Spree", "source_name": "Trefis", "published_at": "2026-07-08T22:37:28", "published_display": "08 Jul 2026 22:37", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories highlights its role in drug development as investors assess long-term gro", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPeXZ6cS0tSG4tdnJHSXBiUThJN0tZMlU3b2pXa1pmWllsazBqV2VCb1Rob0JTdHdRY2NDRy1pWTRnTEZCMGozZjYwalVaa3dUeFRVMUo1eWFBUUpza1N6WEliQzBmYk9HNVl4MUZSelFXRktBbTc0TWFWVmM3TGE5c0dHbGVHSWRNOUpMS3o4ZmU1S1VZQWhlZklBYjhKS3NxZng2WEdHQ2l3bXY5bWc1bTVzaUg0SnBVQlRZU3ROcExxMjVKQ3RZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T06:59:40+00:00", "published_display": "08 Jul 2026 06:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs business profile and stock context", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNemVURTByY0w5TmtWdDVJVlFvTVZJWXAxZEdWODBySkE3aWQzdFlIZDRWVTVzVEh4UzlsNDcyOFNweks4cGk5RWFyc1ZoT1oyUEFnd3BXaDZqbnBBVmlBank0YzZZVEUzc1JObi1YM2FuOG9JVFZkdFlobzBxaXRzVzBhd1ZEQ3l6bktTRks5aFpmNUhleXFfeEFIendBQU5abEJZc2luMlBCdVJMRU93TTN3?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T14:23:27+00:00", "published_display": "07 Jul 2026 14:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Analyst Upgrades Signaling a Turning Point in Charles River\u2019s (CRL) Biopharma Pipeline Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNV25MMlViSHhBYWxLOFdJVUZlamI2dnl3Wk5GeC0zSUxIRTdXbk5YNTlLZThZSmxjVHlqMk5EZHptR251YzBoNEgzaFRFcXM2V1RTWDhpY0FHRjVwcVRPU21yZUJCZkMyc24wS1NJTnJvLVU3cGFraWREbV90ZFVicFF5aFNHY0xfQkkySEpWYUZlbFg1bTJaMUI0aUpKeFA3?oc=5", "source_name": "Market source", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T10:23:36+00:00", "published_display": "03 Jul 2026 10:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs faces a thin catalyst day. Focus stays on earnings and cash flow.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSm9xam1RbDREVXBRQnNhWTBjSXlUNXdQTk5ycV8tMGJPNW96MTFRcmZGeTR1eWV1elZwQ1l1T2dmLVRrejJpeDNUM2psM0NUZVVvQV9sdEstZDlNeWFhTzJ3UEpCZDlab1k2MjlVWXVUVGNLYzV3SVl3SHBCemxQWU1wTGIzVWxnMW1jbzNTQ25fREZ3eWkwWm1BSzFwZmFsY3JqYXhjYU5qc044Rkt2UHFFeGhVZDJoSFc3VENYRjc3bnpGMDJvcXlIVQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T05:44:07+00:00", "published_display": "02 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories updates operations strategy as research demand evolves", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQa21lQjV3b3FxMHJUZkY5Mmtya3FBQlRIYUNLN1QxZHV0SHBaMlZ6bGFhR3BvNlBpQnlVTkVWZ3pLeW5HaHNqR2ZCal9IWWlvLU9oSTVJTkVMSGh4M1U1eDJvbFYza3RKcW84WVc5TkRKSGxBU191eW9CMHFaSFI4dlRRR0pnX0hDZ0kwWW83RHhVamJrbjBpTkRZbVhyam5PUmFTNXRxbXU5MERuN1BpdzdwTkpBY3FEcVg1dlV6alhOYlNXU2RuN0VHZmo?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-01T15:10:51+00:00", "published_display": "01 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPRDczRlVfY2htbWR6cV9hcDZIMnVrQkFnOUxDTFkyNFd4ZXRzVUJ4SjJnczFQWHRCc1pWZUJWMm5nRUdyR0RQNGxxak04RF9Pc2xWOUt6SXlPdC1uMm5BWGs0end3M293V2hSN3MzOWR2aWVXVXkzajJZTlJLOERBeFVSZjZPWXFsQ0psaTA5eHE5T1hHTGp2RS1hUlp5dWJPWUVQWHMxQVhzekpkd0E?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPczNMN20yNHR2Yk9lOEFESTI5RkJZWFNfdm5TUmhpYjJPb2pqcG5iVC1TZlRISzN3Q0ZlY1k5TzgxdGNoSmtpM1J1dnpJVF9aTjloa1hNcXpWemNsdDQxNlpYcWlCMVJoTXkxSFFMd1MwREQ1ZU5OWFhOTUFxU0xDRi1Hc1FWQjNoSGJueFVCeDVTUjdlcmlZTVd5WjJzWnpLSU5CUEVfMTVHOUtEdW8yZ3J0VmdjbFM2NXE4N1Z3TVJKT29PaXd4Z2RVR2E?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Is Charles River Laboratories\u2019 Stock Performance Compared to Other Health Care Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQZ1RERmhfd1BTVnNjRmdKSGVMQUt3XzdYTEc3WTVfUHlkV09KRFFReVNqNVMxU0RxQXNNVEYxT1FSVjA0SkxoTjFGN3I1bU80OUtJZEo4R2FBQ1JpZzBUYUVGQ1ZhZW10WlRnTXREYk9wbERKb3dxelphZ2NqSE9qb1pCWURWcTUzYnpBUUdxVTAzWWdxWDBtRjZMSE1UaTRzd2VEMUxoY3hScENZdXc?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Stock (US1591881009): Labcorp comparison puts valuation in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNanlkemFKTjNQMXVHVngxdXRULXZCdGo2clcyaU5mYnBXcDY0emFkaDNpMHkyUXRER1pWNVJJQkFDdmlYRTI5WjNrMVQxaU5nclZ2Z19ZamNIU2hFSGFLaUU0ZEVRT2JkYWQ3QXY4TmwyVDJuNEIzcGZGdE1waF82UkdIZ3dKVHJqeThrOGhJSXpxYV9GLWhjVWRmRXp5Tk1lWWlQTHhMRW9LaUViOVZCaG5OZ2c0T21uMWVUUlpibjgyT3lsNUxZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-16T14:20:01+00:00", "published_display": "16 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories Stock (US1591881009): shares in focus after recent earnings and valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNbU9salMxeWI5b3R1STZWUDF0TXhRS29RdWdya0Z4MHMwOUJ0dmZsTDVPYi05QUpnMVluYk16MVNFVW1tM2tDNUNLYWd2dzNlMmJLVTBhSmtnX3JqLWctQ3A4QVVOSDBhQ0RTdHdFcUlLcHV3UExqMFJoOUZEV3BNbUJfVnNUalZRVDhoYnpXTE0wNXZpc1BNcnE5UThOdVV2SFU2dmtPOWZVNEpob1kxaFFaUGFyaEhLYkN1TXBybmw5OHJu?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Charles River Laboratories Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZXhOem5tYVhvM3RFcE5hb29wZ3J2X3VXdXM1YXBrWjFFWUdNNWlwelNHTDhVclE2d2pzeDBMc2hEOGVsNmNZMzRKdjljai1ld052dEFaaE03QTVsODRXZFp4Wm9iNWxVUWJLX19nQVNWUDA5Z3VTeEJHcTJvZFZ1TjdOU3ZaeE5keU9abWFnYnBhVkgwNTdabE1FNXZZbWQ3cjVJ?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Charles River (NYSE: CRL) gets 1,438-share equity grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQQzg5TEgwNUNoTFk1QXQtSDBDaEw5NWxXWmFjZkdhTWIwOE0zaDVwU25GS25XYVpCSVdLQ3ZwS3QtZFNTdmpIX1hnczQtMjFaVUFDT2k1d1MwSDktQ0JoY2dkRURuY2R0ZEFWVm5ZMW1xblBmWU5Gb0xhYkhSR0dHU1FsMW5HRkR4VXZfT1J3VWRSRkRQa3c2T3IzNEZqdTl6UkVMcFduc0lLaEFXbndtVnAtV3FSN1RtX0FDaTZuMUdxWUF1UjFiS013?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQclYwUDdHSTNXdndxcTdDbTAyOFo2c0IxX2F2eERqRHVleGVxcUZ5S2dNVE43NlR4WUNRVWRzcEdqdUpvdGZzbEhjQzdwc0FuRlVPVU1YMTB1RnlYYnpJOWROSVRCTU4zclg3NWFLdVZ4WVBUUHZ0QVFXY2ctYWIxNjV4UVpQb1QxakhFVEhfS2NoZXB0NHdqeV9aSkNEX2tnbHZ3NzNoUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQM0N0d3hxcF9xcU1ldDVDcExtUk5fMHRSakxVMXVaZ19ac2NtbU05Mk54X3hlSVZWUWh4eGdlRFg3VkJvNjV2N19Da1dYN0E3WHVDbWt0UmVodG1yX2I5emtSYUdTbDNVbGN2S29vb3pGMnE1X0tUdkNqcWRITEtiVlRnMEZVdnAwTW1uaEFKRTZWTUNLdlZhYXFYaXhDN0U5aU0wckhuRVk?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC (CRL) holds 7.0% of Charles River Labs; 3.456M shares disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPazJ6RFJqRXNqbHNWRF8wSDQxVUlaRVF4NlJDYTJHQ2xJMjRfXzFUanVzWl9FYnBEN1lUOVZuc2tNZ0ZmWkNkSjI0aDI5OHhZUC1hSmxPWUd2dFhJT3dydVNieU1PcllHaEJrd0g5U2FHbjU5NUtHT2VaOFFaQU9PcnR4RHM3Xy1mR1JHRDJfS2t4RV94T1JvWll2RHlfOTFkSDh0dXNmLTJkWWx1X2IwRGpwbnpxSHFYR1JiSVVmcGpnUU5GaU9LVF9B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Charles River Labs Stock: Strong Performance vs. Underlying Business Challenges - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNWkZFOGYyTVhxVFlndzc0U3ljTW1yVWVHaTZBYjhzVjJxdl8zZ1ZZVEpYaGctYWlyTHAzNUk2Uk55eHo2ZXJlcnh5cVlfR1VJeVM0cGhhck84SGpIQjZpNTY4cnlsMGZ0TzRkX01ObElFMlBTMm9haGsxOExxMlZaVHRkZUljTm1ObTZHdklXeTA1NkZGX1dwU0hvWk9xYXY4ZTRXMzdFeFcwNG8?oc=5", "source_name": "IndexBox", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Charles River Laboratories International Stock Sliding, Have You Assessed The Risk?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNcjlCYmhvV0xtajBuTmJPUDlLRzJEV0tmQ0p2bl9qZmhoLXd5SFNyN25OWnJlN1ZSTnl6aVlfRml2QnltMXZ5QUd2Q3NKVEQxTjlza1JjSW5TRXhBUjVqY0xiSGQ3LWhuSVdUbk9ydF8tbGRBRG80QzNPWl9fcVNKSHdzcUxWTzU3RTZTby1yTm5nRVZ0cWFuMWhzOFhkS3lyREZBbmFEMDBhNTZ6OVFYYkZxbmRJaEp0WXdMcF9sUGdEd0NRS0ZXWTJkWlNnRVdiSXdLcHFsbmJFclhRSDRj?oc=5", "source_name": "Trefis", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 102, "total_relevant": 49, "sentiment_summary": {"positive": 21, "negative": 3, "neutral": 25, "score": 60, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.25, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 233.41, "latest_week": "2026-07-10", "one_week_move": 1.2, "four_week_move": 24.5, "twelve_week_move": 26.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.16754, "market_dynamics_buy_signal": false, "relative_strength": 17.714495, "fair_value_gap": 23.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.3741, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.2% over one week, +24.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Ad Hoc News", "count": 8}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "MarketWatch", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Analyst action", "count": 10}, {"label": "Earnings", "count": 6}, {"label": "Deals and strategy", "count": 5}, {"label": "Macro sensitivity", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.2% over one week, +24.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River\u2019s Cell Therapy Moat or Stretch CRL Too Thin?"}], "updated_at": "2026-07-16T11:52:45.954413+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}